cancel
Showing results for 
Search instead for 
Did you mean: 

BLOG: Will PSA testing be replaced? Novel screening approaches.

Chris_McNamara
Community Manager
Community Manager
0 0 38

Banner_Novel Screening.jpg

For now PSA (prostate specific antigen) is the most widely used screening test (as discussed in previous blogs). But there is a large amount of research examining other ways to determine who gets screened and how they will be screened. Prostate cancer screening was very topical at the recent European Association of Urology (EAU) virtual meeting in July. Some new blood tests and formulas have been suggested along with imaging to guide algorithmic developments. This blog will focus on some of these clinical trials.

To start with, its important to review the risk factors for developing prostate cancer:

  • Increasing age (>50 years)
  • Development of symptoms (urination difficulty/blood in sperm) [Other conditions can cause these symptoms however – but they must be checked)

The following factors are considered high risk:

  • > 40 years of age with a father, brother or son who has been diagnosed with prostate cancer, especially if they were diagnosed when they were young
  • family history of prostate, breast or ovarian cancer, especially BRCA1 and BRCA2 gene germline mutations.
  • Black African ancestry

What is a genetic germline mutation? A gene change in a body's reproductive cell (egg or sperm) that becomes incorporated into the DNA of every cell in the body of the offspring. Germline mutations are passed on from parents to offspring.

The current EAU guidelines (2021) recommend genetic germline testing in the following instances:

  • Metastatic prostate cancer
  • High risk prostate cancer and a family member diagnosed with prostate cancer <60 years of age
  • Multiple family members diagnosed with prostate cancer at age <60 years or a family member who died from prostate cancer
  • In those with high-risk germline mutation or a family history of multiple cancers on the same side of the family.

At the EAU meeting a screening algorithm has been proposed based on age, PSA level, PSA density and patient risk factors1. From this stratification MRI and consequently a prostate biopsy is offered based on risk. According to their research, only 10% of men 50-59 years old and 25% of men 60-70 years old would move on to risk stratification. PSA density alone results in 30% fewer referrals for MRI and prostate biopsy. The ultimate goal is 50% immediate reduction of overdiagnosis and overtreatment.

The PROBASE trial in Germany (2014-2019), is a risk-adapted screening study for prostate cancer based on age and baseline PSA alone2. They found that further diagnostic testing in young men should only be initiated if an increased PSA level is confirmed on a second test.

The prevalence of prostate cancers in 45 year old’s is very low and that of unfavorable cancer is even lower.

The MVP trial in Canada compared MRI to PSA. The results have not been published but preliminary findings suggest that MRIs are useful on their own with reduced prostate biopsies required but more cancer being diagnosed, including clinically significant cancers.

The Stockholm3 MRI trial, which is another risk-adapted screening protocol uses a genomics test and MRI3. STHLM3RS is a blood test that analyses PSA and 4 proteins, 101 genetic markers, and clinical information (family history, age, earlier biopsies, and use of 5-alpha reductase inhibitors). The aim of this study was to compare traditional screening with a web-based risk prediction combined with MRI-targeted biopsies for prostate cancer screening. They found that combining the Stockholm3 test with an MRI target biopsy for cancer screening decreases overdiagnosis while maintaining detection of clinically significant prostate cancer.

In Australia, the National Institute of Integrative medicine is trialling a new screening blood test which detects circulating tumour cells (CTC) called ISET4. Preliminary published findings show the test to be highly sensitive and accurate for detecting prostate cancer. It will be interesting to see the long-term outcome of this study. The trial team are actively recruiting for the next phase of the trial.

While these screening approaches are still experimental, one tried and trusted test remains: the PSA Test. It is very important for those who are at high risk to start testing from age 40 or 45, every 2 years till age 69, with the starting age depending on the strength of family history.

 

Reference:

  1. Van Poppel H, Hogenhout R, Albers P et al. Early detection of prostate Cancer in 202 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol. 2021 Mar; 79(3):327-329.
  2. Arsov C, Becker N, Herkommer K, Gschwend J, Imkamp F, Kuczyk M, Hadaschik B, Hohenfellner M, Siener R, Kristiansen G, Schimmoller L, Antoch G, Albers P. The German risk-adapted prostate cancer screening trial (PROBASE): first results after recruitment of 30.000 men. Eur Urol, 2018; s17(2), e372‐e373.
  3. Tobias Nordstrom, Discacciati A, Bergman M, Clements M, Aly M, Annestedt M et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. The Lancet Oncology 2021; 22(9): 1240-1249.
  4. Ried K, Tamanna T, Matthews S, Eng P, Sali A. New screening test improves detection of prostate cancer using circulating tumour cells and prostate-specific markers. Frontiers in Oncology 2020; 10: 582
Kalli Spencer.png

 

 

 

 

 

 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.

 

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.